Would you consider using avacopan in PR3+ mononeuritis multiplex without other systemic involvement?

I would certainly consider using avacopan in AAV mononeuritis multiplex. While we don't know the outcomes of mononeuritis in avacopan-treated patients specifically, ~20% of patients in the ADVOCATE trial (Jayne et al., PMID 33596356) had neuropathy and the outcomes overall suggest a robust response across all organ manifestations since the primary outcome in the trial was BVAS of 0. Neuropathy in AAV does not tend to be more refractory than other manifestations (unlike subglottic stenosis and or...